Full Press Release Details
libtayo cemiplimab neoadjuvant treatment demonstrates encouraging event free survival in patients with resectable cutaneous squamous cell carcinoma cscc.
REGN
libtayo cemiplimab neoadjuvant treatment demonstrates encouraging event free survival in patients with resectable cutaneous squamous cell carcinoma cscc
Key Takeaway: libtayo cemiplimab neoadjuvant treatment demonstrates encouraging event free survival in patients with resectable cutaneous squamous cell carcinoma cscc